Konrad Klinghammer

charité university hospital

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (16)

Collaborators (11)

Andreas E. Albers

Medical School Berlin

Anja E. Hauser

Ulrich Keller

Charité - Universitätsmedizin Berlin

Max Heiland

Charité - Universitätsmedizin Berlin

Dominik Geisel

Steffen Koerdt

Kevin Harrington

Head of Division of Radiotherapy and Imaging

Institute of Cancer Research

UNITED KINGDOM

Tanguy Seiwert

Johns Hopkins University

UNITED STATES

Ingeborg Tinhofer-Keilholz

Charité - Universitätsmedizin Berlin

Daniel Zips

Chair, Professor, Director

Charité - Universitätsmedizin Berlin

Paul Jank

Head of Translational Research Laboratory

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Konrad Klinghammer

Research Interests

Explore related searches

Contact this professor

Articles (16)

Collaborators (11)

Andreas E. Albers

Anja E. Hauser

Ulrich Keller

Max Heiland

Dominik Geisel

Steffen Koerdt

Kevin Harrington

Tanguy Seiwert

Ingeborg Tinhofer-Keilholz

Daniel Zips

Paul Jank

Make your next move.

Konrad Klinghammer

Research Interests

Explore related searches

Contact this professor

Articles (16)

Benefit from adjuvant radiotherapy in early-stage oral cavity and oropharyngeal cancer with solitary ipsilateral lymph node metastasis - A population-based study on German cancer registry data.

INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

A macrophage-predominant immunosuppressive microenvironment and therapeutic vulnerabilities in advanced salivary gland cancer.

MicroRNA-mediated PTEN downregulation as a novel non-genetic mechanism of acquired resistance to PI3Kα inhibitors of head & neck squamous cell carcinoma.

Reduced monocytic IL10 expression in PD1 inhibitor-treated patients is a harbinger of severe immune-related adverse events.

Essential data variables for a minimum dataset for head and neck cancer trials and clinical research: HNCIG consensus recommendations and database.

Molecular subtyping of head and neck cancer - Clinical applicability and correlations with morphological characteristics.

The impact of time between surgery and adjuvant chemoradiotherapy in advanced oral cavity squamous cell carcinoma.

Tolerability and efficacy of the cancer vaccine UV1 in patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma planned for first-line treatment with pembrolizumab - the randomized phase 2 FOCUS trial.

Diving into hot topics of salivary gland carcinoma management-an EORTC young and early career investigator survey.

Targeted treatment in a case series of AR+, HRAS/PIK3CA co-mutated salivary duct carcinoma.

Multiparametric Phenotyping of Circulating Tumor Cells for Analysis of Therapeutic Targets, Oncogenic Signaling Pathways and DNA Repair Markers.

Predictors for Adherence to Treatment Strategies in Elderly HNSCC Patients

Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors.

Treatment Stratification in First-Line Recurrent or Metastatic Head and Neck Cancer, on Behalf of the EORTC Young Investigator Head and Neck Cancer Group.

Disulfiram Acts as a Potent Radio-Chemo Sensitizer in Head and Neck Squamous Cell Carcinoma Cell Lines and Transplanted Xenografts.

Collaborators (11)

Andreas E. Albers

Anja E. Hauser

Ulrich Keller

Max Heiland

Dominik Geisel

Steffen Koerdt

Kevin Harrington

Tanguy Seiwert

Ingeborg Tinhofer-Keilholz

Daniel Zips

Paul Jank

Make your next move.